Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
1g |
|
||
5g |
|
||
Other Sizes |
|
ln Vivo |
When MAG was administered at high and medium doses (10 and 30 mg/kg), the rise in lung W/D weight ratio was much lessened. The generation of TNF-α and IL-1β was effectively decreased by pretreatment with MAG (10 and 30 mg/kg). MAG (10, 30 mg/kg) dramatically decreased the expression of NF-κB p65 protein when compared to LPS. In contrast, MAG (10 and 30 mg/kg) dramatically boosted I���B-��� expression compared with the LPS group, while LPS considerably decreased IκB-α protein expression [1]. At the 14- and 21-day time intervals, AST, ALT, TBIL, and TBA levels were significantly lower in the low-dose and high-dose MAG treatment groups compared to the RIF and INH groups. This suggests that MAG has a protective effect against liver injury generated by RIF and INH. The MAG-treated group of RIF and INH-treated rats showed a protective effect against RIF, as evidenced by the significant decrease in MDA levels at the 14- and 21-day time points and the increase in hepatic GSH levels at the 7, 14, and 21-day time points. INH-related liver damage [2].
|
---|---|
References |
[1]. Huang X, et al. Anti-Inflammatory Effects of Monoammonium Glycyrrhizinate on Lipopolysaccharide-Induced Acute Lung Injury in Mice through Regulating Nuclear Factor-Kappa B Signaling Pathway. Evid Based Complement Alternat Med. 2015;2015:272474.
[2]. Zhou L, et al. Monoammonium glycyrrhizinate protects rifampicin- and isoniazid-induced hepatotoxicity via regulating the expression of transporter Mrp2, Ntcp, and Oatp1a4 in liver. Pharm Biol. 2016;54(6):931-7 |
Molecular Formula |
C42H65NO16
|
---|---|
Molecular Weight |
839.97
|
CAS # |
53956-04-0
|
Related CAS # |
Glycyrrhizic acid;1405-86-3;Dipotassium glycyrrhizinate;68797-35-3
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
O([C@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C(=O)O[H])O1)O[H])O[H])O[C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C(=O)O[H])O1)O[H])O[H])O[H])[C@@]1([H])C([H])([H])C([H])([H])[C@@]2(C([H])([H])[H])[C@@]([H])(C([H])([H])C([H])([H])[C@@]3(C([H])([H])[H])[C@]4(C([H])([H])[H])C([H])([H])C([H])([H])[C@@]5(C([H])([H])[H])C([H])([H])C([H])([H])[C@@](C(=O)O[H])(C([H])([H])[H])C([H])([H])[C@@]5([H])C4=C([H])C([C@@]32[H])=O)C1(C([H])([H])[H])C([H])([H])[H].N([H])([H])[H]
|
Synonyms |
Ammonium glycyrrhizate 18β-Glycyrrhizic acid monoammonium salt (+)-Glycyram
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~119.05 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.98 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.98 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.98 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.1905 mL | 5.9526 mL | 11.9052 mL | |
5 mM | 0.2381 mL | 1.1905 mL | 2.3810 mL | |
10 mM | 0.1191 mL | 0.5953 mL | 1.1905 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.